pharmaphorum

JULY 5, 2021

Parexel’s chief executive Jamie Macdonald said that in the past 18 months, the company “has continued its strong growth trajectory” in a market for outsourced clinical services that at conservative estimates is expected to grow at a rate of 8% to 9% in the coming years.

Clinical Trials 62

Clinical Trials Clinical Trials Regulation Trials 62

pharmaphorum

SEPTEMBER 8, 2022

It is a similar approach to that of another form of oncology treatment that is also experiencing a surge of interest, antibody-drug conjugates (ADCs). Big pharma has already noted its interest in the area, as seen in Novartis’ investments. The drug was added to Novartis’ portfolio through a $2.1

Manufacturing 102

Manufacturing Development Drugs Antibody 102

pharmaphorum

MAY 14, 2021

Swiss biotech MoonLake Immunotherapeutics has emerged with what it hopes is one of the hottest drugs in inflammatory diseases, sonelokimab. Arnout Ploos van Amstel is no stranger to the cut-throat world of inflammatory disease drugs, a market that is worth billions and has spawned some of the biggest blockbusters ever.

Licensing 59

Licensing Licensing Drugs Marketing 59

Drug Discovery World

OCTOBER 4, 2022

Several of the large pharma companies have recently re-entered the dementia field. The last several years has seen an exponential rise in the understanding of the pathophysiology of AD and in the identification of clinically predictive biomarkers. Diseases such as PSP and FTD have no licensed and available treatments.

Development 52

Development In-Vivo Compound Screening Clinical Development 52

Drug Discovery World

MARCH 29, 2023

Politico published a summary of the key propositions outlined in the draft 2 , and DDW’s Multimedia Editor Megan Thomas investigates their intention, and observes how the industry has responded. Key proposals Approved drugs must launch in all EU countries within two years Politico described this as a measure to ensure a level playing field.

Clinical Trials 52

Clinical Trials Clinical Trials Production Medicine 52

pharmaphorum

SEPTEMBER 29, 2020

As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and gene therapies. As a result, there is a need for continued innovation and increased efficiency in terms of drug development to manage cost, complexity and speed to provide potentially transformative therapies for cancer patients.

Research 126

Research Gene Editing Gene Development 126

pharmaphorum

JANUARY 29, 2021

US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has just added another to its pipeline via a licensing agreement with Japan’s Asahi Kasei worth up to $410 million. The new drug has already cleared phase 1 single and multiple ascending dose and clinical pharmacology studies, according to Lilly.

Licensing 52

Licensing Licensing Bioavailability Antibody 52

pharmaphorum

AUGUST 4, 2020

Shares in Redx Pharma were soaring this morning after it licensed its preclinical fibrotic disease drug RXC006 to AstraZeneca. The company’s shares were valued as high as 95p on the London Stock Exchange following the announcement, the highest they had been since 2015.

Drugs 90

Drugs Clinical Trials Clinical Trials Pharma Companies 90

pharmaphorum

MAY 21, 2021

Arecor Therapeutics is planning to float on the London stock market, to raise funding and awareness for its developmental portfolio of biologic drugs, which are based on already-marketed drugs reformulated to provide extra benefits for patients. . We have been well known within pharma with the tech platform that can deliver. “We

Insulin 52

Insulin Drugs Production Marketing 52

pharmaphorum

NOVEMBER 12, 2020

The mid-sized pharma group has also signed a collaboration with Florida, US-based Lacerta Therapeutics , adding more AAV capsids – well established as a staple for delivering gene therapy sequences – as well as another gene therapy candidate. The post UCB revs up its gene therapy drive with Handl acquisition appeared first on.

Gene Therapy 52

Gene Therapy Gene Manufacturing Contract Manufacturing 52

Drug Discovery World

OCTOBER 7, 2022

Earlier this year, Cancer Research UK (CRUK) launched its innovation engine, Cancer Research Horizons, to streamline drug discovery through the combination of its commercial and therapeutics teams. RA: How can the integration of industry and academia help streamline drug development? . This is about changing how we operate.

HR 52

HR Research Drugs Development 52

The Pharma Data

NOVEMBER 5, 2020

The demand for an effective drug for nail fungus is high and MOB-015 can achieve a unique market position through its high antifungal effect,” says Anna Ljung, CEO of Moberg Pharma. MOB-015 is the next-generation nail fungus treatment targeting both OTC and prescription markets worldwide.

Marketing 40

Marketing Production Regulation Containment 40

XTalks

SEPTEMBER 5, 2023

Xtalks spoke with Maria Reyes Boceta-Muñoz, Clinical Operations Head of Development R&D at GlaxoSmithKline in Spain, Portugal & Israel, to understand the current vaccine development climate and where the sector is headed. It is affected by factors such as complacency, convenience, confidence and cultural factors.

Vaccination 96

Vaccination Vaccine Development Clinical Trials 96

Pharmaceutical Technology

MAY 26, 2023

The British company’s expanded facilities boasts of 11 suites, including two class B filling suites with class A filling cabinets, warehousing and quality control laboratory capability. One big pharma company has already given the seal of approval with a successful customer quality audit.

DNA 130

DNA Manufacturing Gene Therapy Gene 130